BKC,

Nice find. I can't seem to access the manuscript, but from the abstract it sounds very similar to the findings reported in Zenith's AACR poster from 2015, as well as some of the data presented in the Zenith Corporate Update presentation.

Interestingly, that paper used both JQ1 and OTX-015. JQ1 is not a clinical candidate, but OTX-015 from Oncoethix (recently acquired by Merck) is in clinical trials. One OTX-015 trial for Glioblastoma Multiforme was recently terminated on 12/17/15 and another for Acute Myeloid Leukemia (AML) was withdrawn prior to enrollment. They still have one active trial for AML/Diffuse Large B-Cell Lymphoma set to be completed Sept 2016 and another for various selected advanced solid tumors (NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer (CRPC), Pancreatic Ductal Adenocarcinoma) set to be completed December 2016.

As stated in the Zenith corporate update presentation,

• Oncoethix only has a single BETi drug, OTX-015

• Limited efficacy in Phase 1 Trials

• It is a Benzodiazepine program which have been hampered by extensive cardiovascular safety in clinical monitoring

Best regards,

BearDownAZ